Background
CD47/SIRPα axis
The essential function of the CD47/SIRPα interaction
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
Non-Hodgkin lymphoma (NHL)
Hodgkin lymphoma (HL)
Multiple myeloma (MM)
Type of mAb | Subclass of IgG | Initial time of clinical studies | Phase | Type of tumors | Treatment programs | ClinicalTrials.gov Identifier | |
---|---|---|---|---|---|---|---|
Hu5F9-G4 | mAb | IgG4 | 2014.8 | Phase II | MDS and AML | Combined therapy | NCT02216409 |
Hu5F9-G4 | mAb | IgG4 | 2020.9 | Phase III | Higher-risk MDS | Combined therapy | NCT04313881 |
Hu5F9-G4 | mAb | IgG4 | 2021.11 | Phase II | R/R cHL | Combined therapy | NCT04788043 |
Hu5F9-G4 | mAb | IgG4 | 2021.12 | Phase I | R/R B-Malignancies | Combined therapy | NCT04599634 |
Hu5F9-G4 | mAb | IgG4 | 2022.05 | Phage III | TP53 Mutant AML | Combined therapy | NCT04778397 |
Hu5F9-G4 | mAb | IgG4 | 2022.9 | Phase IB/II | MDS and AML | Combined therapy | NCT05367401 |
TTI-621 | SIRPα fusion protein | IgG1 | 2016.1 | Phase IA/IB | Hematological Malignancies | Monotherapy | NCT02663518 |
TTI-621 | SIRPα fusion protein | IgG1 | 2021.10 | Phase IB | MM | Combined therapy | NCT05139225 |
TTI-622 | SIRPα fusion protein | IgG4 | 2018.5 | Phase IA/IB | Hematological Malignancies | Combined therapy | NCT03530683 |
TTI-622 | SIRPα fusion protein | IgG4 | 2021.1 | Phase IB | R/R MM | Combined therapy | NCT05139225 |
ALX148 | IRPα fusion protein | IgG1 | 2017.2 | Phase I | Lymphoma | Combined therapy | NCT03013218 |
ALX148 | SIRPα fusion protein | IgG1 | 2020.1 | Phase I/II | MDS | Combined therapy | NCT04417517 |
ALX148 | SIRPα fusion protein | IgG1 | 2021.1 | Phase I/II | B-NHL | Combined therapy | NCT05025800 |
ALX148 | SIRPα fusion protein | IgG1 | 2021.5 | Phase I/II | AML | Combined therapy | NCT04755244 |
AK117 | mAb | IgG4 | 2020.4 | Phase I | Lymphoma | Monotherapy | NCT04349969 |
AK117 | mAb | IgG4 | 2021.1 | Phase I | Lymphoma | Monotherapy | NCT04728334 |
AK117 | mAb | IgG4 | 2021.5 | Phase I/II | Higher-risk MDS | Combined therapy | NCT04900350 |
AK117 | mAb | IgG4 | 2021.7 | Phase IB/II | AML | Combined therapy | NCT04980885 |
Gentulizumab | mAb | Un | 2021.4 | Phase I | NHL | Combined therapy | NCT05221385 |
Gentulizumab | mAb | Un | 2021.4 | Phase I | R/R-AML or MDS | Monotherapy | NCT05263271 |
IMM-01 | SIRPα fusion protein | IgG1 | 2019.9 | Phase I | Lymphoma | Monotherapy | ChiCTR1900024904 |
IMM-01 | SIRPα fusion protein | IgG1 | 2022.1 | Phase I/II | MDS and AML | Combined therapy | NCT05140811 |
SRF231 | mAb | IgG4 | 2018.3 | Phase IA/IB | lymphoma/CLL | Combined therapy | NCT03512340 |
SHR1603 | mAb | IgG4 | 2018.1 | Phase I | Lymphoma | Combined therapy | NCT03722186 |
IBI188 | mAb | IgG4 | 2018.12 | Phase I | lymphoma | Combined therapy | NCT03717103 |
IBI188 | mAb | IgG4 | 2020.8 | Phase IB | Newly Diagnosed HR-MDS | Combined therapy | NCT04511975 |
IBI188 | mAb | IgG4 | 2020.9 | Phase IB | AML | Combined therapy | NCT04485052 |
IBI188 | mAb | IgG4 | 2020.9 | Phase IB | Newly Diagnosed HR-MDS | Combined therapy | NCT04485065 |
TJC4 | mAb | IgG4 | 2019.5 | Phase I | lymphoma | Combined therapy | NCT03934814 |
TJC4 | mAb | IgG4 | 2021.6 | Phase IB | MDS and AML | Combined therapy | NCT04912063 |
TJC4 | mAb | IgG4 | 2022.1 | Phase IB | Multiple Myeloma | Combined therapy | NCT04895410 |
ZL-1201 | mAb | IgG4 | 2020.5 | Phase I | Lymphoma | Combined therapy | NCT04257617 |
IMC-002 | mAb | IgG4 | 2020.6 | Phase I | Lymphoma | Combined therapy | NCT04306224 |
AO-176 | mAb | IgG2 | 2020.11 | Phase I/II | Multiple Myeloma | Combined therapy | NCT04445701 |
CC-95251 | mAb | IgG4 | 2019.2 | Phase I | Hematological Cancers | Combined therapy | NCT03783403 |
CC-95251 | mAb | IgG4 | 2022.1 | Phase I | MDS and AML | Combined therapy | NCT05168202 |
CD47 | mAb | Un | 2021.12 | Single-arm | Recurrent AML After Transplantation | Combined therapy | NCT05266274 |
Combination of CAR-T cells and CD47/SIRPα blockers
CD47/SIRPα-targeted antibody–drug conjugate (ADC)
PD-1/PD-L1 axis
MHC-I/LILRB1/2 axis
CD24/sialic acid-binding Ig-like lectin 10 (SIGLEC-10) axis
Elimination of macrophages using either CSF1 or CSF1R inhibitors
CD47/SIRPα-targeted bispecific antibodies (BsAbs)
CD47/CD20 BsAb
CD47/CD19 BsAb
CD47/4-1BB BsAb
CD47/CD33 BsAb
CD47/PD-L1 BsAb
CD47/PD-1 BsAb
CD47/CD38 BsAb
SIRPα/CD70 BsAb
SIRPα/CD123 BsAb
CD47/CD3 BsAb
Name | Initial time of clinical studies | phase | Type of tumors | ClinicalTrials.gov Identifier | Outcome measures |
---|---|---|---|---|---|
TG-1801 (NI-1701) | 2021.4 | Phase IB | B-cell lymphoma or CLL | NCT04806035 | To determine the recommended phase II dose (RP2D), ORR |
IMM0306 | 2021.8 | Phase I | R/R CD20-positive B-NHL | NCT04746131 | Maximum Tolerated Dose (MTD) of IMM0306 as measured by incidence of DLTs (Dose Limiting Toxicity) |
IBI-322 | 2021.5 | Phase I | Hematological malignancies | NCT04795128 | treatment related AEs, ORR |
IBI-322 | 2021.12 | Phase IA/IB | Myeloid Tumor | NCT05148442 | Treatment related AEs, ORR |
DSP107 | 2021.9 | Phase IB/II | MDS, AML and T-cell lymphoproliferative disease | NCT04937166 | Treatment related AEs, Dose Limiting Toxicities (DLT), ORR, MRD |
HX009 | 2021.12 | Phase I/II | R/R-lymphoma | NCT05189093 | Treatment related AEs, ORR, PFS, DOR, DCR, PK/PC |
JMT601 (CPO107) | 2021.12 | Phase I/II | Advanced CD20-positive NHL | NCT04853329 | To determine the recommended single-agent CPO107 RP2D, safety, efficacy |
SG2501 | 2022.4 | Phase IA/IB | R/R hematological malignancies and lymphoma | NCT05293912 | To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy |
Challenges of CD47/SIRPα-targeted BsAbs
With Fc fragments | Without Fc fragments | |
---|---|---|
Advantages | CMC: Better solubility Better stability Therapeutic effect: Including ADCC and CDC effects, multiple mechanisms to enhance cancer-killing effect Longer half-life | CMC: Easy to produce High productivity Small molecular weight Therapeutic effect: The therapeutic effect is only through antigen binding, with low immunogenicity and fewer side effects |
Disadvantages | Some structural CMCs are more complex, mostly with higher aggregation, mismatch and low purification rates If the molecular weight is too large, the permeability to the tumor tissue will be poor | Need to develop specific purification technology routes Shorter half-life, higher dosing frequency and poor patient tolerance |
Reprogramming pro-tumor macrophages as anti-tumor macrophages
Anti‑MARCO therapy
TLR agonists
T cell immunoglobulin and mucin domain containing 4 (Tim-4) blockade
Chimeric antigen receptor-macrophage (CAR-M)
Preclinical studies of CAR-M
Clinical studies of CAR-M
Source of CAR-M | Target antigens | CAR Structure | Generation | Stage | Preclinical results | Refs |
---|---|---|---|---|---|---|
J774A.1 | CD19 and CD22 | CD19 + Megf10 CD19 + FcRV CD19 + FcRV + PI3K | 1st generation | Preclinical evaluation | CD3ζ, FcRγ and Megf10 intracellular domains demonstrate similar phagocytic activity in vitro and PI3K recruitment domain enhances phagocytosis of whole tumor cells CD47 mAb enhances the phagocytic activity of CAR-M in vitro; | 212 |
iPSCs | CD19 | CD19 + 4–1BB + CD3ζ | 2nd generation | Preclinical evaluation | CAR-iMACs demonstrate pro-inflammatory/anti-tumor state in vitro CAR-iMACs can expand, persist and exert anti-tumor activities in vivo | 64 |
Raw264.7 | HER2 | HER2 + CD147 | 1st generation | Preclinical evaluation | CAR-147 induces MMP expression in vitro and in vivo, but does not enhance phagocytosis of tumor cells CAR-147 lowers collagen content, increases CD3+ T cell infiltration and inhibits the proliferation of tumor | 214 |
Raw264.7 | CCR7 | CCL19 + TLR2, TLR4 + TLR6 + MerTk + 4-1BB + CD3ζ | 2nd generation | Preclinical evaluation | In vitro, MerTK (CAR-M) kills and phagocytoses cells more efficiently than CAR-M that has other intracellular domains CAR-M (MerTK) inhibits the progression of tumors, prolongs survival time, and inhibits tumor metastasis in mice with minimal toxicity Cancer cells treated with CAR-M (MerTK) exhibit significant CD3+ T cell infiltration, a decrease of PD-L1-positive cells, as well as an increase in pro-inflammatory cytokines | 66 |
Monocytes | HER2 | HER2 + CD3ζ | 2nd generation | Phase I Ongoing clinical trials (CT0508) against HER2+ solid tumors | Injection of adenoviral vector leads to M1-like macrophages and pro-inflammatory microenvironment in the tumor An adenovirus-transduced CAR macrophage is capable of cross-presenting tumor-derived antigens and activating T lymphocytes more effectively An adenovirus-transduced CAR macrophage significantly prolongs survival time and decreases metastasis in mice harboring tumors; | 65 |
Human THP-1 | CD19 | CD19 + CD3ζ | 2nd generation | Preclinical evaluation | CAR-M enhances antigen-dependent phagocytosis in vitro | 65 |
Murine BMDM | ALK | ALK + CD8 Hinge + CD28 TM + CD28 CSD + CD3ζ + IFN-γ | 3rd generation | Preclinical evaluation | CAR-M enhances antigen-dependent phagocytosis CAR-M induces M1 polarization, upregulates antigen presentation, increases T cell activations, and reduces tumor burden | 215 |
Monocytes | CD5 | Un | mRNA engineered | Phase I Ongoing clinical trials (MT-101) against PTCL | Un | Un |